GLI1 and Familial prostate cancer: In line with these data, administration of the dual PI3K/mTOR inhibitor NPV-BEZ-235 has been shown to suppress GLI1-dependent cancer cell proliferation in androgen-independent prostate cancer cells (Yang et al., 2017).